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Nicotinamide is a water-soluble amide form of niacin (nicotinic acid or vitamin B3). Both niacin and nicotinamide are widely
available in plant and animal foods, and niacin can also be endogenously synthesized in the liver from dietary tryptophan.
Nicotinamide is also commercially available in vitamin supplements and in a range of cosmetic, hair, and skin preparations.
Nicotinamide is the primary precursor of nicotinamide adenine dinucleotide (NAD+), an essential coenzyme in ATP production
and the sole substrate of the nuclear enzyme poly-ADP-ribose polymerase-1 (PARP-1). Numerous in vitro and in vivo studies have
clearly shown that PARP-1 and NAD+ status inﬂuence cellular responses to genotoxicity which can lead to mutagenesis and cancer
formation. This paper will examine the role of nicotinamide in the protection from carcinogenesis, DNA repair, and maintenance
of genomic stability.
1.Introduction
Nicotinamide (pyridine-3-carboxamide; Figure 1(a) is an
amide active form of Vitamin B3 or niacin (pyridine-3-
carboxylic acid; Figure 1(b). Both nicotinamide and niacin
are precursors for the synthesis of nicotinamide adenine
dinucleotide (NAD+) and the phophorylated derivative
NADP+ [1]( Figure 2). Nicotinamide and niacin are readily
available from plant and animal foods, and niacin can be
endogenously synthesized from the amino acid tryptophan
[2], which constitutes ∼1% of protein in the diet [1].
The main dietary sources of nicotinamide and niacin are
various meats, liver, yeast, dairy products, legumes, beans,
nuts, seeds, green leafy vegetables, fortiﬁed bread, cereals,
coﬀee, and tea [1, 3]. Uncooked foods mostly contain
NAD+ and NADP+, which can be enzymatically hydrolysed
to nicotinamide in the process of cooking [1]. Studies in
adult humans in the 1950s estimated that around 60mg
of tryptophan is hepatically converted to 1mg of niacin,
which is equal to 1 niacin equivalent (NE) [1]. Vitamins
B2 (riboﬂavin) and B6 (pyridoxine) in addition to iron
are needed as cofactors for conversion of tryptophan to
niacin [1, 3]. The ability to convert tryptophan to niacin
varies greatly between individuals and is enhanced by
protein and tryptophan deﬁciency, and it is depressed by
excessive dietary leucine [1]. The adult recommended daily
intake expressed as niacin equivalent is 16NE/day for men,
14NE/day for women and 18NE/day and 17NE/day for
pregnant and lactating women, respectively [4]. In humans,
dietary nicotinamide and niacin are absorbed from stom-
ach and intestine via both sodium-dependent and passive
diﬀusions [1]. Most tissues take up both forms of vitamins
to synthesize NAD+ and NADP+, although nicotinamide
is the preferable substrate [5]. Dietary NAD+ and NADP+
are hydrolyzed by intestinal mucosal and hepatic NAD
glycohydrolases to release nicotinamides into the portal or
systemic circulation [1]. Niacin is also endogenously synthe-
sized from dietary tryptophan via kynurenine pathway and
quinolinate (Figure 2), and this supplies most of the body’s
niacin requirements [1]. Niacin and quinolinate are further
converted to nicotinic acid ribonucleotides and then into
NAD+ [1]. Excess nicotinamide and niacin are methylated
in the liver to form N1-methylnicotinamide (NMN) and
N1-methylnicotinic acid (NMNA), respectively [1]. NMN is
further oxidised into N1-methyl-4-pyridone-3-carboxamide
(4-pyr) and N1-methyl-2-pyridone-5-carboxamide (2-pyr)
[1]. Niacin is also metabolized in the liver into glycine
conjugate and nicotinuric acid [6]. These metabolites are2 Journal of Nucleic Acids
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then renally excreted [1]. Some cosmetic preparations
also contain nicotinamide. Systemic absorption of topical
nicotinamide has been reported to be approximately 10%
depending on the vehicle used [7]. Adverse eﬀects of
nicotinamide are rare and have occurred mainly with high
oral doses (≥6gram/day), which include nausea, vomiting,
liver toxicity, headache, fatigue, and dizziness [8–10]. Unlike
niacin, nicotinamide is not a vasodilator, thus it rarely causes
ﬂushing [11].
Severe nicotinamide deﬁciency in humans causes the
disease pellagra (Italian “pelle agra”; “rough skin”), which
is characterised by photosensitive dermatitis, diarrhoea,
dementia, and death [3]. It was thought that the clinical
manifestations of pellagra arise from the deﬁcient NAD+
and NADP+ levels in maintaining energy for cellular
functions [13]. However, understanding of these multiple
symptoms has progressed with the ﬁnding of NAD+ as a
substrate for poly(ADP-ribose)polymerases (PARPs) [14].
PARP has been recognized to play multitude roles in
DNA damage responses, including DNA repair, maintenance
of genomic stability, transcriptional regulation, signaling
pathways involving apoptosis, telomere functions, and other
multiple cellular functions [15]. Several members of the
PARP family have been identiﬁed, of which PARP-1 is the
most reported and is the focus of this paper. NAD+ has also
been shown to be a free radical scavenger [16–20] and is
directly used for the synthesis of cyclic ADP-ribose, which
may be involved in calcium signaling pathways leading to
apoptosis or necrosis [21, 22]. Cellular NAD+ status has
been increasingly demonstrated to alter the cell susceptibility
to genotoxic damage [23], highlighting the crucial role of
nicotinamide as a NAD+ precursor in modulating pathways
involved in carcinogenesis. This paper will ﬁrst discuss
nicotinamide and carcinogenesis in humans and whole
animal models. Next, the roles of nicotinamide in relation
to DNA repair, genomic stability, and mutagenesis will be
examined.
2.Nicotinamide,Niacin,andCancerinHumans
There are relatively few epidemiological studies on the asso-
ciation between nicotinamide intake and cancer in humans.
Deﬁciencyofnicotinamideandothermicronutrientsinclud-
ing riboﬂavin, zinc, and magnesium have been linked to
the increased frequency of oesophageal cancer in certain
populations in China and Italy [24, 25]. Low dietary niacin
has also been associated with an increased frequency of oral,
gastric, and colon cancers, as well as oesophageal dysplasia
[25–27]. In the Linxian trial in China, involving nearly
30,000 residents, 40mg niacin and 3.2mg riboﬂavin were
supplemented in one of the treatment arms daily for over
5 years. It was shown that this combined supplementation
decreased oesophageal cancer incidence and mortality by
14% and 10%, respectively [24]. Most human studies have
examined the dietary intake or supplementation of niacin
in combination with other micronutrients [24, 25, 28–32].
The impact of niacin on human carcinogenesis is therefore
confounded by the eﬀect of other micronutrients. Analysis
from a large Western population within The Malm¨ oD i e t
and Cancer Study in Sweden showed that approximately
15%–20% of individuals in this population were niacin
deﬁcient [33]. While severe niacin deﬁciency resulting in
pellagra is uncommon in Western populations, suboptimal
niacin intake may be relevant in populations at risk such as
cancer patients and individuals with high occupational or
environmental exposure to genotoxic agents including ion-
izing radiation, ultraviolet radiation (UVR), and alkylating
agents. Limited studies indicate that cancer patients are at
risk of niacin deﬁciency [34, 35]. In one trial involving 42
patients with various primary cancers, it was shown that
40% of these patients were niacin deﬁcient as measured by
abnormally low urine levels of the niacin metabolite N1-
methylnicotinamide [34]. Chemotherapy may also depress
NAD+ levels [35] and precipitate pellagra by promot-
ing anorexia and malabsorption. Some chemotherapeutic
agents (e.g., 5-ﬂuorouracil, 6-mercaptopurine) also inter-
fere with tryptophan conversion to niacin [36]. Moreover,
chemotherapeutic alkylating agents have been shown to
cause miscoding lesions, chromosomal aberrations [37], and
secondary cancer, particularly leukemia, which complicates
chemotherapy in 10%–15% of cancer survivals [38]. More
direct evidence comes from studies in rats, which showed
that niacin deﬁciency signiﬁcantly increases the risk of
chemotherapeutic-induced secondary leukemia [39]. Niacin
and NAD+ levels are important determinants of genomic
responsestogenotoxicinsults[23].Maintaininganoptimum
nicotinamide level is therefore essential in cancer patients
and individuals at risk of exposure to genotoxic agents.
3. Nicotinamide Supplementation and
AnimalModels of Carcinogenesis
Animal models show that nicotinamide supplements inﬂu-
ence carcinogenesis in a dose-dependent and organ-speciﬁc
manner (Table 1). Nicotinamide is not carcinogenic by itself
at doses more than 300-fold above requirement, admin-
istered to mice throughout their life span [40]. Overall,
low-dose nicotinamide (dose range of 150–200μM, topical;
0.25%–2.5%, oral; 30mg/kg body weight (bw) intraperi-
toneal) appears to be protective in various chemical- and
UVR-induced carcinogenesis models in animals. Nicoti-
namide at dietary concentrations of 0.25%–2.5% is pro-
tective against urethane-induced pulmonary adenoma inJournal of Nucleic Acids 3
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Figure 2: The simpliﬁed pathways for nicotinamide, niacin, NAD
+, and PARP-1 metabolism. Dietary nicotinamide, niacin, and tryptophan
are precursors for the synthesis of NAD
+, essential in ATP production and PARP-1 activation. Nicotinamide can be converted to niacin
by bacterial nicotinamidase in the intestinal lumen. PARP-1 is activated by DNA strand breaks, cleaving NAD
+ into nicotinamide and
ADP-ribose.Poly(ADP-ribose)glycohydrolase(PARG)reactivatesPARP-1byremovingpoly(ADP-ribose)polymers,allowingforcontinuous
NAD
+ utilization. Figure is adapted from Jacobson et al., in 1995 [6] and Meyer-Ficca et al., in 2004 [12].
mice, whereas 0.25% niacin did not show the same pro-
tection [41, 42]. However, higher concentrations of dietary
niacin (0.4%) caused a 6% reduction in the incidence of
nonlymphocytic leukemia induced by ethylnitrosourea in
Weanling male Long-Evans rats [43]. Nicotinamide has
also been shown to inhibit the growth of transplanted
murine breast adenocarcinoma in mice, although the doses
required are higher (2.5% and 5% diet; 1000mg/kg bw
intraperitoneal) than those needed to suppress carcinogen-
induced cancers [44, 45]. The eﬀect of nicotinamide on
diethylnitrosamine (DEN)-, streptozotocin-, and heliotrine-
induced carcinogenesis seems to be organ-speciﬁc. Massive
doses of nicotinamide (350–500mg/kg bw intraperitoneal,
multipledosing)inhibitedDEN-inducedlivertumours(34%
reduction), but promoted DEN-induced kidney neoplasia
(44%increase)inWistarrats[46].However,inanotherstudy
ofDEN-inducedcarcinogenesis,evenlow-dosenicotinamide
(0.082% and 0.37% oral) increased the incidence of DEN-
induced kidney tumours from 5% in controls (DEN only)
to 28% and 59%, respectively, in male F344 rats [47].
0.37% nicotinamide by itself had no eﬀect on tumour
formation [47], suggesting that the presence of carcinogen
is required for the tumour promoting or inhibiting eﬀect of
nicotinamide.
Intraperitoneal nicotinamide (350mg/kg) increased the
incidence of streptozotocin-induced pancreatic islet-cell
tumours in male Holtzman rats from 4% in controls
(streptozotocin only) to 64% [48] ,b u ti td e c r e a s e dt h e
incidence of renal adenomas from 77% to 18% [49].
Nicotinamideadministeredintraperitoneallyat500mg/kgto
white male weanling rats before and after administration of
pyrrollizidine alkaloid heliotrine increased pancreatic islet-
cell tumours [50]. The varying eﬀects of nicotinamide with
diﬀerent carcinogens and target organs may reﬂect the
diﬀerential susceptibility of each organ to DNA damaging
agents. Furthermore, it has been shown that PARP-1 protein
expression is tissue- and/ or cell-type speciﬁc [51], and
there are tissue and species diﬀerences in requirements
for NAD+ precursors. Tissues with high cellular turnover
including breast, lung, and skin have higher NAD+ require-
ments, and mice are relatively more resistant to niacin
deﬁciency compared to rats or humans [23]. Hence, the
breast, lung, and skin tissues of rats and humans likely
required higher doses of NAD+ precursors in the face of
genomic insults.
4. Nicotinamide: Photoimmunosuppression
andSkin Cancer
The immune system is an important defense mechanism
that prevents potentially cancerous cells from developing
into tumors. In humans, the importance of immunity in
preventing cancer is observed in renal transplant recipients
on immunosuppressive medications. In this population,
there is an increased incidence of all cancer type (13.7-
fold increase), nonmelanoma skin cancer (33-fold increase),
and melanoma (3.3-fold increase) compared to age-matched
immune competent individuals [58]. Ultraviolet (UV) radi-
ation in sunlight is the primary initiator of skin cancer by4 Journal of Nucleic Acids
Table 1: Animal models of nicotinamide or niacin eﬀect on carcinogenesis.
Animal Carcinogen Form of nicotinamide
(dose) Organ Eﬀect on tumor Ref.
Mouse None Oral All None [40]
Mouse UV Topical(200μM) Skin Inhibition [52]
Mouse UVB Oral (niacin)(0.5%; 1%
diet) Skin Inhibition [53]
Mouse TPA Topical (150μM) Skin Inhibition [54]
Mouse DMBA and Croton oil Oral(0.2% diet) Skin None [55]
Mouse Urethane Oral (0.25%; 0.4% diet)
Oral (niacin) (0.25% diet)
Lung Inhibition
[41] Lung None
Mouse Urethane Oral (1%; 2.5% diet) Lung Inhibition [42]
Rat ENU Oral (niacin) (0.4% diet) Bone marrow
(haemopoeitic cells) Inhibition [43]
Rat Bracken fern Oral (0.5% diet) Intestine Inhibition
[56] Bladder Inhibition
Hamster BOB ip (30mg/kg bw) Pancreas Inhibition [57]
Rat DEN ip (350–500mg/kg bw) Kidney Increase
[46] Liver Inhibition
Rat DEN Oral (0.082%; 0.37%) Kidney Increase [47]
Rat Streptozotocin ip (350mg/kg bw) Pancreas Increase [48]
Rat Streptozotocin ip (350mg/kg bw) Kidney Inhibition [49]
Rat Heliotrine ip (500mg/kg bw) Pancreas Increase [50]
Mouse Transplanted murine
breast adenocarcinoma Oral (2.5%; 5%) Recipient subcutaneous
tissue Inhibition [44]
Mouse Transplanted murine
breast adenocarcinoma ip (1000mg/kg bw) Recipient subcutaneous
tissue Inhibition [45]
causing DNA damage in the skin and also by suppressing
cutaneous immunity, even at exposure doses 25% to 50% of
those required to cause mild sunburn [59]. Both UVB (290–
320nm) and UVA (320–400nm) in sunlight are immune
suppressive [60, 61]. UV-induced DNA damage, particularly
in the form of cyclobutane pyrimidine dimers (CPDs), is an
important molecular trigger for UV-induced immunosup-
pression [62]. Agents that can modulate DNA repair and
prevent UV-induced immunosuppression may thus reduce
skin cancer.
In mice, 200μM topical nicotinamide [52] and 0.5% and
1% niacin-supplemented diets [53] have both been shown to
markedly protect against UV-induced immunosuppression
and signiﬁcantly reduce the incidence of UV-induced skin
tumours. In these studies, UV-induced immunosuppression
was measured by passive transfer assay, whereby splenocytes
from irradiated mice enhanced the growth of antigenic
tumours in unirradiated, recipient mice [52, 53]. Topical
nicotinamide also slowed down the rate of skin tumour
development [52] and the eﬀect of oral niacin on tumour
inhibition was greater with increasing dose [53]. Oral niacin
increased skin NAD+ levels, which were reduced by UVR in
mice not receiving niacin, and this was thought to contribute
to tumour prevention [52, 53]. It was also suggested that
protection from photoimmunosuppression is a mechanism
by which nicotinamide and niacin prevent UV-induced
carcinogenesis [52, 53].
Using the Mantoux model of delayed-type hypersen-
sitivity (DTH) in healthy volunteers, we have shown that
nicotinamide protects from UV-induced immunosuppres-
sioninhumans[63,64].5%topicalnicotinamide,applied15
minutes before or after each of 3 daily exposures to low-dose
solar-simulated (ss) UV (equivalent to less than ∼8m i n u t e s
exposure to Sydney spring sunlight [65]), prevented UV-
induced suppression of Mantoux reactions [63]. 5% topical
nicotinamide, applied immediately after a single exposure
to narrowband UVB (300nm) or UVA (385nm), protected
against immunosuppression by both wavebands [66]. Using
the same model, oral nicotinamide has also been shown to
protect skin immunity in humans [64].
5. Nicotinamide, PARP-1 andDNA Repair
The role of nicotinamide in DNA repair and maintenance
of genomic stability is tightly related to its functions as
an NAD+ precursor and a substrate for PARP-1. PARP-
1 is a nuclear enzyme which detects DNA damage, binds
to DNA single or double strand breaks, and then uses
NAD+ as a substrate to form nicotinamide and ADP-
ribose.Subsequentenzymaticreactionsleadtotheformation
of branched ADP-ribose polymers on a nuclear acceptor
protein [67, 68]( Figure 2). Poly(ADP-ribosylation) of the
acceptor protein has been hypothesized to function in DNA
repair by modifying structural proteins proximal to DNAJournal of Nucleic Acids 5
strand breaks, facilitating the opening of the condensed
chromatin structure, which is required for the recruitment of
DNA repair complexes [69, 70]. The major acceptor proteins
of poly(ADP-ribose) are PARP-1 itself, and auto-poly(ADP-
ribosylation) results in downregulation of the enzyme [70].
Other major acceptor proteins reported are histone, topoi-
somerase I and II, DNA polymerase α and β, DNA ligase I
and II, nuclear retinoid X receptor, nuclear factor (NF)-κB,
and p53 [70, 71]. Poly(ADP-ribose) glycohydrolase (PARG)
is the main enzyme involved in catabolism of poly(ADP-
ribose), cleaving it into free ADP-ribose monomers [70].
PARP-1 itself is also known to be part of chromatin structure
and involved in maintaining a compact chromatin structure,
preventing inadvertent transcription from occurring [72].
Unfolding of the compact chromatin structure allows DNA
regulatory and repair processes access to the damaged sites as
well as to replication and transcription initiation sites [73].
PARP-1 has been reported to play a key role in the nucleotide
excision repair (NER) pathway used to remove bulky DNA
adducts [74] and in the base excision repair (BER) pathway
by interacting with BER protein XRCC1 (X-ray repair cross-
complementing 1) [75–78]. PARP-1 is involved in main-
taining chromosomal integrity by protecting broken DNA
frominappropriatehomologousrecombinationduringDNA
repair and replication [79, 80]. PARP knockout mice exhib-
ited dramatically increased sensitivity to ionizing radiation
andalkylatingagents[81–83]andshoweda2-3-foldincrease
in spontaneous sister chromatid exchange (SCE) and ampli-
ﬁed SCE and micronuclei (MN) formation induced by
carcinogens [83, 84]. PARP-null mice also showed extreme
sensitivity to nitrosamine-induced carcinogenesis [85], had
shorter telomeres, and increased end-to-end chromosomal
fusions, aneuploid cells, and chromosome fragments [86].
Thus, nicotinamide is involved in maintenance of genomic
stability by providing a substrate for PARP-1, preserving a
cellular energy reserve for ATP-dependent DNA repair [87]
and enabling preservation of PARP-1 integrity [88].
6. The Inﬂuence of NAD
+ Status on
GenomicStabilityand DNA Repair
6.1. In Vitro Studies. Al a r g en u m b e ro fin vitro studies
reported that NAD+ status inﬂuences genomic stability and
sensitivity to cytotoxic eﬀects of DNA-damaging agents.
Nicotinamide (50–500μM) increased intracellular NAD+
and enhanced the repair of DNA damage induced by N-
methyl-N
 -nitro-N-nitrosoguanidine (MNNG) in cultured
primary human mammary epithelial cells [23]. Preincuba-
tion with 74μM nicotinamide prevented NAD+ depletion
after dimethyl sulphate (DMS) exposure and increased
strand break rejoining rate [89]. Increasing NAD+ status by
the addition of nicotinamide thus improved the capacity
of DNA repair. NAD+ is also an important determinant of
skin cell survival following UV radiation. 0.1 and 33μM
nicotinamide added to UV-irradiated cultured human skin
ﬁbroblasts increased cell survival 7 days post irradiation
in a dose-dependent manner [90]. Even in the absence
of genotoxic stress, NAD+ depletion increased spontaneous
DNA damage in human HaCaT keratinocytes, which was
reversible with the addition of nicotinamide [91]. NAD+
status is therefore critical in preserving genomic function
of skin cells. Furthermore, it was shown that skin NAD+
levels are negatively correlated with malignant phenotype in
human skin cancers. Normal skin from patients with pre-
malignant actinic keratoses had signiﬁcantly higher NAD+
than normal skin from patients with cutaneous squamous
cell cancers [23].
Exposure of ex vivo human lymphocytes to oxygen
radicals [92], UVB [93, 94], Υ-irradiation [95], N-methyl-
N
 -nitro-N-nitrosoguanidine(MNNG)[93,94],ordimethyl
sulfate (DMS)[93] resulted in reduced intracellular NAD+,
with numbers of DNA-strand breaks inversely correlated
with NAD+ levels [92]. Addition of 2–5mM nicotinamide
prevented this lowering of NAD+ levels, stimulated unsched-
uled DNA synthesis (UDS), and increased DNA repair [93–
95]. The ability of nicotinamide to enhance DNA repair
depends on the presence of functional repair mechanisms.
Xeroderma pigmentosum is an autosomal recessive genetic
disorder of DNA repair, in which the ability to repair DNA
damage caused by UVR is deﬁcient. [96]. In the presence
of 2mM nicotinamide, lymphoctyes from these patients
exhibited increased UDS after MNNG treatment but failed
to show increased UDS after UVB irradiation. Normal
lymphocytes incubated with the same dose of nicotinamide,
in contrast, showed increased UDS and enhancement of
DNA repair after UVB or MNND exposures [97].
In HaCaT cells (human keratinocyte cell line) NAD+
depletion upregulated NADPH oxidase activity with conse-
quent increase in reactive oxygen species (ROS) production.
NAD+ repletion with nicotinamide completely reversed the
ROS accumulation [91]. In support of these ﬁndings, niacin
deﬁciency, which results in intracellular NAD+ depletion
in rats, also caused an increase in both protein carbonyls
and 8-oxo-7,8-dihydro-2 -deoxyguanosine (8-oxo-dG) in
bone marrow [98]. Oxidative-induced DNA damage 8-
oxo-dG is a miscoding lesion, which generates GC→TA
transversion mutations by pairing with an adenine instead
of a cytosine during replication [99]. ROS also damages
other cellular components including cell membranes by
peroxidation of fatty acids within the phospholipid bilayer
and proteins by forming carbonyl derivatives [100]. Lipid
peroxidation increases production of prostaglandins (PG),
including PGE2, which is known to play an important
role in inﬂammation. Inﬂammation in premalignant actinic
keratoses has been reported to be a marker of progression
to squamous cell carcinoma [101]. It was also postulated
that ROS may cause gene mutations in actinic keratoses,
driving their progression to squamous cell carcinoma [101].
Regulation of ROS levels by maintenance of intracellular
NAD+ is therefore important in preventing oxidative DNA
damage and gene mutation.
6.2. In Vivo Studies. Administration of 100mg/day niacin to
two volunteers for 8 weeks protected against ex vivo lympho-
cyte DNA strand breaks induced by hypoxanthine/xanthine
oxidase. The supplementation increased NAD+ concentra-
tions by nearly 5 times baseline levels and signiﬁcantly6 Journal of Nucleic Acids
reduced oxygen radical-induced DNA stand breaks in the
lymphocytes [92].
The impact of niacin deﬁciency in rats has been
extensively studied by the Kirkland group [98, 102–106].
Wenling Long-Evans rats were kept niacin-deﬁcient (ND) or
were pair-fed (PF) either normal dietary niacin or supple-
mental 4mg/gram niacin (NA) (0.4% of diet). The DNA-
alkylating agent ethylnitrosurea (ENU) or the topoisomerase
II inhibitor etoposide (ETO) was then administered to these
rats orally. Bone marrow is a good indicator of niacin
intake. ND diets caused 72%–80% [102, 104]r e d u c t i o ni n
bone marrow NAD+ content, whereas NA diets produced
a 240% increase [103]. Basal poly(ADP-ribose) levels were
also signiﬁcantly lower in ND rats. After ENU- or ETO-
treatment, poly(ADP-ribose) levels were not increased in
bone marrow of ND rats whereas in PF and NA rats, the level
of bone marrow poly(ADP-ribose) rose signiﬁcantly [102,
104]. Adequate NAD+ is therefore essential for the increase
in ADP-ribose polymer metabolism activated by DNA dam-
age. Niacin deﬁciency alone causes increased micronuclei
(MN) formation (6.2-fold), SCE frequency (2.8-fold) [103],
chromosomes breaks (4-fold), and chromatid breaks (2-
fold). With ENU- or ETO-treatment, there were much
greater increases in MN formation, SCE, and chromosomal
aberrations (CA) in bone marrow of ND rats [103, 105].
The increased genomic instability in ND rats is further
evidenced by the reduction in latency and the increase in
the incidence of developing ENU-induced leukemia [102].
Niacin deﬁciency signiﬁcantly delayed DNA repair in bone
marrow after ENU- or ETO-treatment [103, 105]a n dw a s
shown to alter p53 expression and impair ETO-induced cell
cycle arrest and apoptosis [104].
7. Nicotinamide, PARP-1, and
Cellular Responses to DNA Damage
The activation of PARP-1 by DNA strand breaks can lead to
three cellular pathways depending on the intensity of DNA-
damaging stimuli [70]( Figure 3). In the case of relatively
mild DNA damage, PARP-1 activation enhances DNA repair
by interacting with p53 protein, signaling cell-cycle arrest,
and facilitating DNA repair enzymes, including XRCC1 and
DNA-dependent protein kinases to access damaged DNA
[70]. When DNA damage is irreparable, PARP-1 activation
induces apoptotic cell death by activating NF-κBp a t h w a y
and preventing ATP depletion and DNA repair through
caspase-mediated PARP-1 cleavage [70, 107]. In contrast,
extensive DNA damage leads to PARP-1 overactivation,
depleting its substrate (NAD+). As cells consume ATP in an
attempt to replenish NAD+, this leads to a cellular energy
crisis, which precipitates necrotic cell death [70]. Apoptosis
is an energy-dependent process [108–111] thus cells severely
deﬁcient in energy are unable to proceed through apoptotic
cell death.
PARP-1 is inhibited by nicotinamide and its analogues
such as 3-aminobenzamide and metoclopramide [112, 113].
PARP-1inhibitionbynicotinamideinvitrohasbeenreported
to delay the rejoining of DNA strand breaks [95, 114, 115],
induce UDS [95, 97, 116], and increase the frequency of
spontaneous SCE [117, 118]. It has been suggested that high
dose of nicotinamide (5mM or more) inhibits DNA repair
through PARP-1 inhibition while low dose nicotinamide
enhances rejoining of DNA strand breaks through provision
of NAD+ [114]. However, it is argued that nicotinamide
is unlikely to inhibit PARP in vivo [119]. Rats fed nicoti-
namide 33 times above normal requirements exhibited 2-
fold increases in basal poly(ADP-ribose). After exposure to a
hepatocarcinogen, induction of poly(ADP-ribose) was only
marginally higher in the nicotinamide supplemented rats
[120], suggesting that a much higher dose of nicotinamide is
required to possibly inhibit PARP-1 in the whole organism.
Excessive PARP activity is however detrimental to cells.
A u g m e n t e dP A R Pa c t i v i t yc a u s e db yr e a c t i v eo x y g e ni n j u r y
to cultured pulmonary-artery endothelial cells resulted in
NAD+ and ATP depletion and necrotic cell death, which
was prevented by the PARP-1 inhibitors nicotinamide and
3-aminobenzamide (3-AB) [121]. Ex vivo murine lung
exposed to bleomycin, a DNA-cleaving antitumor antibi-
otic, caused acute lung injury through sustained PARP
activation and NAD+ depletion. This injury was pre-
vented in the presence of 3-AB [122]. The topical PARP
inhibitor, BGP-15M (O-(3-pyperidino-2-hydroxy-1-propyl)
pyrimide-3-carbocylicacidamidoximemonohydrochloride)
reduced UVB-induced DNA strand breaks in hairless mouse
skin and prevented excessive production of poly(ADP-
ribose) induced by moderate UV doses. These ﬁndings
suggest that the inhibition of PARP-1 overactivation, and
therefore of NAD+ and ATP depletion, can occur without
negative consequence to DNA repair [123].
PARP-1 inhibition by nicotinamide has been shown to
switch the mode of cell death from necrosis to apoptosis in
ex vivo human lymphocytes treated with hydrogen peroxide
[124].Inaddition,ithasbeenwidelyreportedthatinthecells
exposed to oxidative stress, both ATP and NAD+ levels serve
as crucial molecular switches between apoptosis and necrosis
[125–133]. Nicotinamide as a precursor of NAD+,A T P ,
and as an endogenous inhibitor of PARP-1 therefore plays
signiﬁcant roles in cellular protection and in determining
cellular fate in response to genotoxic DNA damage.
8. Nicotinamide, PARP-1, and Regulation of
GeneExpression
PARP-1 has been reported to frequently associate with tran-
scriptionally active regions of chromatin [134, 135]. PARP-1
is a transcription coactivator of nuclear factor-κB( N F - κB)
[136], a transcription factor that plays a signiﬁcant role in
regulation of genes involved in a variety of cellular processes
including immune and inﬂammatory responses, apoptosis,
cell proliferation, and diﬀerentiation [137, 138]. There is a
large amount of literature supporting the involvement of
NF-κB in cutaneous carcinogenesis [136, 139]. Epidermal
inﬂammationpromotestumorprogression[101]andNF -κB
is known to be one of the mediators involved [139]. PARP-
1 knockout mice are much less sensitive to inﬂammatory
stress [140, 141] and PARP-1 deﬁcient mice exhibitedJournal of Nucleic Acids 7
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Figure 3: PARP-1 and cellular responses to DNA damage. The intensity of DNA damage determines cellular pathways: survival, apoptosis,
or necrosis. In the case of mild DNA damage, poly(ADP-ribosylation) enhances DNA repair and thus cell survival. When the damage is
beyond repair, PARP-1 facilitates apoptosis, preventing ATP depletion and DNA repair through PARP-1 caspase-mediated cleavage. Severe
DNA damage leads to PARP-1 overactivation, cellular energy depletion, and necrotic cell death. Figure is adapted from Vir´ ag and Szab´ o, in
2002 [70].
substantially reduced sensitivity to the carcinogenic eﬀect
of DMBA and TPA on the skin [136]. In PARP-1 null
(parp-1−/−) mice, the development of skin papillomas
induced by DMBA and TPA was signiﬁcantly delayed
and reduced in numbers compared to control (parp-1+/+)
mice. PARP-1 inhibition in mice with 3,4-dihydro-5-[4-(1-
piperidinyl)butoxyl]-1(2H)-isoquinoinone (DPQ) also had
the same eﬀect [142]. PARP-1 inhibition with nicotinamide
and benzamides was also shown to inhibit NF-κBi nv i t r o
and suppress lipopolysaccharide-induced TNF-α production
in mice [143]. Indirect inhibition of NF-κB by elimination
or inhibition of PARP-1 may prevent activation of κB-
target genes, leading to suppression of inﬂammation and
expression of genes associated with tumor progression [136].
Although PARP-1 knockout mice as mentioned previously
have increased genomic instability in response to alkylating
agents and ionizing radiation [81–83] and were more
recently shown to be more sensitive to nitrosamine- [85]a n d
azoxymethane-induced cancers [144], it is thought that this
controversy can be explained by the unique environmental
and intrinsic factors involved in tumorigenesis of diﬀering
genotoxic agents and organs [136].
PARP-1 inhibition by DPQ or by genetic deletion of
PARP-1inmicewasalsofoundtonormalizeordownregulate
some upregulated genes in DMBA/TPA-treated skin, includ-
ing several tumor-associated genes in mouse and human
and genes involved in oxidative stress, inﬂammation, and the
immuneresponse.Ofparticularimportanceistheabsenceof
induction of Hif (Hypoxia inducible factor)-1α in the PARP-
1 deﬁcient and DPQ-treated murine skin [142]. The tran-
scription factor Hif-1α promotes the adaptation of tumour
cells to hypoxia, including angiogenesis, vasodilation, glu-
cose transport, and anaerobic metabolism [145]. It was also
noted that in the tumours of DPQ-treated mice, there were
increased apoptotic cells, suggesting that inhibition of Hif-
1α may contribute to tumour death through failure of these
cells to adapt to hypoxia [142]. In our research group,
topical nicotinamide was found to normalize subsets of
apoptosis,energymetabolism,andimmunefunction-related
genes that are downregulated by UVR in human skin [63].
Low dose of ssUV was shown in this study to downregulate
apoptotic genes BCL2, TP53, IGF1R, PRKCA, and AKT1,
which are also involved in the regulation of telomerase
activity, and thought to play important roles in the initiation
of skin carcinogenesis [63, 146]. Normalisation of these
subsets of genes by nicotinamide suggests its involvement
in apoptosis and early events in skin carcinogenesis. The
downregulation of genes for energy production in ssUV-
treated skin supports evidence for the cellular energy decline
knowntobeinducedbyUVR[90].Aspreviouslymentioned,
DNA repair requires ATP [87], and an adequate NAD+
level is critical in maintaining the genomic integrity of skin8 Journal of Nucleic Acids
cells during UV radiation [90]. Consistent with its role as
an NAD+ and ATP precursor, nicotinamide protects the
cell from UVR-induced energy depletion. Nicotinamide also
normalized ssUV downregulation of TP53 genes. p53 is a
key regulator of cell cycle arrest and apoptosis in response
to DNA damage [147]. In response to genotoxic stress, p53
is stabilized and activated by posttranslational modiﬁca-
tions, including poly(ADP-ribosyl)ation, phosphorylation,
and acetylation [148, 149]. Niacin deﬁciency in rats [104]
and nicotinamide depletion in cultured cells derived from
breast, lung, and skin cells [23] caused decreased expression
of the tumor suppressor protein, p53. PARP-1 inhibition
has been shown to decrease basal p53 levels and impairs
p53 stabilization after DNA damage [150]. In addition,
PARP-1 deﬁcient cell lines exhibit a signiﬁcant reduction in
both baseline p53 expression and its activity compared to
normal wild type cells [150]. Diminished p53 function is
highly associated with malignancy in breast, lungs, and skin
[151]. Nicotinamide prevented UV-induced downregulation
of p53, suggesting its mode of protection from genotoxic
eﬀect of UVR. The eﬀect of nicotinamide on p53 regulation
has also been reported to be independent of PARP [152].
9. Conclusion
Nicotinamide, which is the dietary precursor for NAD+,
provides a substrate for PARP-1 activity. The activation
of nuclear enzyme PARP-1 by DNA strand breaks during
cellular genotoxic stress responses leads to complex signaling
pathway that can enhance DNA repair, result in apoptotic
cell death, or cause cellular energy loss leading to necrotic
cell death. In vivo and in vitro studies showed that NAD+
content of the cells inﬂuences responses to DNA damag-
ing agents. NAD+ depletion impairs ADP-ribose polymer
metabolism and increases genomic instability in the face
of genotoxic and oxidative stress challenges. Nicotinamide
deﬁciency in humans may also contribute to increased
frequency of gastrointestinal cancers in certain populations
although other micronutrient deﬁciencies are likely to be
involved as well. Nicotinamide supplementation in animal
models has opposing eﬀect on carcinogenesis, depending
on the type of carcinogens and target organs. Nicoti-
namide protected against UV-induced immunosuppression
in mice and humans and UV-induced carcinogenesis in
mice. Limited study in humans indicates that skin NAD+
content is an important determinant of malignant pheno-
type.Thus,nicotinamidesupplementationmayinﬂuencethe
progression of premalignant actinic keratoses to malignant
squamous cell cancers. PARP-1 plays a key role in regulation
of genes involved in inﬂammation, apoptosis, and cellular
diﬀerentiation. While PARP-1 inhibition could impair its
role in DNA repair, PARP-1 overactivation is detrimental
to the cells by depleting its substrate NAD+, which leads
to cellular energy crisis and necrotic cell death. In various
murine models, PARP-1 inhibition was shown to favor
apoptotic cell death, reduce inﬂammatory response, and
reduce genomic sensitivity to various carcinogens. However,
extrapolation of these data to human, particularly when
physiological regimes involved in human carcinogenesis,
should be done cautiously. Further studies are needed to
determine the eﬀect of high-dose nicotinamide on in vivo
carcinogenesis and genomic stability of the cancer cells and
the surrounding normal cells.
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